Antibodies against type II collagen (CII) are essential for development of collagen-induced arthritis (CIA), but how and where the B-cell response to CII is initiated is not fully known. We show here that naive DBA/1 mice display naturally reactive IgM and IgG anti-CII producing B cells prior to immunization. The CII-reactive B cells were observed in the spleen and recognized as marginal zone (MZ 
INTRODUCTION
Autoantibody (auto-Ab) production is a characteristic of autoimmune diseases such as rheumatoid arthritis. Correspondingly, in mouse models of autoimmune arthritis, it is well established that Abs play an essential role in disease development. In collagen-induced arthritis (CIA), high titres of IgG against collagen type II (CII) are essential for disease onset and transfer of the IgG to naive mice induces arthritis. 1, 2 In addition, mice lacking activating Fc receptors for IgG (Fc gamma receptors (FccRs)) are protected from CIA, while absence of the inhibitory FccRIIb results in augmented CIA. 3, 4 Thus, FccRIIb is a negative regulator of B cells dampening the signaling strength of the B-cell receptor (BCR) and reducing Ab secretion, particularly in autoreactive B cells. 5 A direct role of B cells in arthritis is further proven in B cell-deficient mice that do not develop CIA. 6 This is also evident in rheumatoid arthritis, where B-cell depletion therapy contributes to a positive clinical response in correlation with a significant drop in auto-Abs. 7 Importantly, low levels of auto-Abs can be detected in the serum many years before clinical symptoms of rheumatoid arthritis, 8 suggesting that an early break in B-cell tolerance is underlying the disease.
In the B-cell compartment tolerance to self-antigen (Ag) is mediated by either clonal deletion, Ag receptor editing or functional silencing through anergy. However, these procedures are naturally not complete and peripheral B cells with low self-reactivity do occur. A subtype of B cells that has shown to be enriched for self-reactivity is the innate-like marginal zone (MZ) B cell. MZ B cells are long lived, noncirculating B cells that reside strategically on the border of the white and red pulp in the spleen, as a first line of defense against blood-borne pathogens. 9 The MZ B cells can respond to low quantities of thymusindependent as well as thymus-dependent Ag and can initiate a rapid Ab response. [10] [11] [12] [13] Further, they are able to transport Ag to the follicles where they can efficiently activate naive T cells and quickly differentiate into plasma cells. 13, 14 The MZ B-cell compartment together with B1 B cells contain a large number of self-reactive clones and are associated with the production of natural Abs, which arise spontaneously at low titres without previous exogenous Ag exposure. 15 Natural Abs are generally of the IgM isotype and are polyreactive, with low affinity towards foreign Ag but also against self-proteins. 16, 17 Interestingly, an expansion of the MZ B-cell compartment has been associated with autoimmunity, as pathogenesis in non-obese diabetic (NOD) mice and in murine lupus is correlated with intrafollicular location of MZ B cells. [18] [19] [20] [21] However, the role of MZ B cells in the autoimmune B-cell response in CIA is still to be explored. We therefore characterized the early B-cell response in the induction of CIA by analyzing different lymphoid compartments of mice immunized with CII. For comparison we immunized a group of mice with a foreign Ag (ovalbumin; OVA) that does not induce autoimmunity. We used the enzyme-linked immunospot (ELISpot) assay, which permits the evaluation of Ag-specific B cells at the single-cell level with regard to frequency. Surprisingly, we discovered a pre-existing anti-CII B-cell response in the spleen of naive DBA/1 mice. The naturally CII-reactive B cells were represented by MZ B cells, which upon CII immunization expanded rapidly. This MZ B-cell response was followed by a later expansion of CII-reactive follicular (FO) B cells in the spleen. In contrast, OVA immunization generated the first OVA-specific Abforming cells (AFCs) mainly in the lymph nodes rather than in the spleen. These results suggest that CII-reactive MZ B cells in the spleen initiate the immune response to CII in CIA.
MATERIALS AND METHODS
Mice NOD, C57BL/6 and arthritis-susceptible DBA/1 mice (Bomholtgaard Ltd, Ry, Denmark) of both sexes were bred and kept in the animal unit at the Uppsala Biomedical Center, Uppsala University, Sweden. Balb/c mice (Bomholtgaard Ltd, Ry, Denmark) of both sexes were bred and kept in the animal unit at the National Veterinary Institute, Uppsala, Sweden. The animals were fed rodent chow and water ad libitum and were negative for routine-screened pathogens. The mice were 6-10 weeks old at the initiation of the experiments. All experiments were approved by the local ethics committee (Uppsala tingsrätt, Sweden).
Collagen preparation
Native CII was prepared from bovine nasal cartilage by pepsin digestion and subsequent purification, as described previously. 22 The CII was solubilized in 0.01 M acetic acid overnight at 14 uC with constant mixing to 2 mg/ml. CII and OVA immunizations and assessment of arthritis For CIA studies CII was emulsified with an equal volume (1 : 1) of complete Freund's adjuvant (Difco, Detroit, MI, USA) to a final concentration of 1 mg/ml. The mice were injected intradermally at the base of the tail with 50 ml of the emulsion, giving a dose of 50 mg of CII per mouse. Mice constituting a control group were immunized in the same way but with OVA (Sigma, Steinheim, Germany). The CIIimmunized mice were inspected 2-3 times a week for arthritis development, starting 3 weeks after immunization, and clinical severity of arthritis was graded, as described previously. 23 
ELISA
The mice were bled by the tail vein at several time points after immunization and Ag-specific IgM and IgG in individual serum samples were measured by ELISA, as described previously. 23 Briefly, sera from CII-or OVA-immunized mice were added to 96-well plates (MaxiSorp; NuncBrand Thermo Fischer Scientific, Roskilde, Denmark), which were coated with BCII and OVA, respectively. After incubation, alkaline phosphatase-conjugated sheep anti-mouse IgM or IgG Abs (Sigma) were added for total Ig measurement and biotin-conjugated goat anti-mouse IgG1, IgG2a, IgG2b and IgG3 Abs (Southern Biotech, Birmingham, AL, USA) for subclass measurement. For detection of IgG subclasses the plates were further incubated with alkaline phosphatase-conjugated ExtrAvidin (Sigma). The plates were washed after each incubation and finally r-nitrophenyl phosphate substrate (Sigma), diluted in diethanolamine buffer (1 mg/ml), was thereafter applied and the absorbance was measured using a spectrophotometer (VersaMax; Moleculare devices, Sunnyvale, CA, USA) at 405 nm.
Cell preparation
Naive or immunized mice were killed at different time points after immunization and the spleen, bone marrow and pooled axillary and inguinal lymph nodes were collected. Individual single cell suspensions were prepared from each lymphoid tissue. Bone marrow cells were flushed with cold phosphate-buffered saline from femurs and kept on ice in DMEM culture medium (Sigma) with 100 U penicillin (Sigma), 100 mg/ml streptomycin (Sigma), 1% L-glutamine (Sigma) and 10% fetal calf serum (Sigma) referred to as complete DMEM medium. The lymph nodes and spleen were carefully pressed through a stainless steel mesh into a single cell suspension. Splenic erythrocytes were lysed by ACK lysis buffer (0.15 M NH 4 Cl, 0.1 mM Na 2 EDTA and 1.0 M KHCO 3 ) and further washed in phosphate-buffered saline. The single cell suspensions of the spleen and the lymph nodes were finally diluted in complete DMEM medium and kept on ice. Cell counts of individual samples were made with trypan blue (Gibco, Grand Island, NY, USA).
Cell isolation and sorting
Mature B cells were sorted from splenocytes by magnetic-activated cell sorting (MACS) followed by FACS sorting, or by FACS sorting only. MACS was performed according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, the splenocytes were labeled with biotin-conjugated anti-mouse CD43 (eBioscience, San Diego, CA, USA) at 4 uC for 20 min. After washing, the splenocytes were incubated with streptavidin microbeads (Miltenyi Biotec) at 4 uC for 30 min. Alternatively, the splenocytes were labeled directly with antimouse CD43 (Ly-48) microbeads (Miltenyi Biotec) and incubated at 4 uC for 30 min. After additional washing, the splenocytes were resuspended in MACS buffer and put on a LS column (Miltenyi Biotec) in a magnetic field. The CD43-positive cells, including T cells and B1 B cells, were retained in the column and the negative cell fraction, containing B cells, was collected. FACS staining with FITC-conjugated anti-mouse CD45R/B220 (clone RA3-6B2; BD Pharmingen, San Jose, CA, USA) verified the B-cell purity to at least 90% (data not shown Figure 1) . Cell sorting using FACS only were performed accordingly: splenocytes were stained with PE-labeled anti-B220 (clone RA3-6B2; BD Pharmingen), biotin-labeled anti-CD1d (clone 1B1; BD Pharmingen) and FITC-conjugated anti-CD23 (clone B3B4; BD Pharmingen) at 4 uC for 30 min. After incubation, the cells were washed twice and incubated for an additional 30 min with streptavidin-conjugated allophycocyanin (APC) on ice (BD Pharmingen). The B220 1 splenocytes were gated and further sorted into MZ B cells, defined as CD1d high CD23 low and FOB cells, defined as CD1d low CD23 high , using a FACS Vantage DiVa and FACS Diva software 5.1 (BD Biosciences). Splenocytes stained with FITC-or PE-conjugated isotype-matched control Abs (BD Pharmingen) were used as negative controls. To determine possible contamination of transitional B cells in the different B-cell populations (MZ and FO B cells), FACS staining was performed. Accordingly, splenocytes, before and after anti-CD43 MACS separation, were stained with biotinylated anti-CD1d, FITCconjugated anti-CD21, PE-conjugated anti-CD23 (all from BD Pharmingen), APC-conjugated anti-IgM (BioLegend) and anti-B220 Figure 1) . 24 In addition, separate staining to elucidate possible expression of CD5 on separated splenocytes was performed. The cells were stained with FITC-conjugated anti-IgD (BD Pharmingen), APC-conjugated antiIgM (BioLegend), pacific blue-conjugated anti-B220 (BioLegend) and PE-conjugated anti-CD5 (BD Pharmingen) for 30 min on ice. The cells were analyzed using FACSAria and the FACSDiva software (BD).
FccRIIb expression
In order to study FccRIIb expression on MZ and FO B cells, splenocytes were stained with PE-labeled anti-CD1d (clone 1B1; BD Pharmingen), FITC-conjugated anti-CD23 (clone B3B4; BD Pharmingen) and biotin-labeled anti-FccRIIb haplotype Ly-17.2 (clone K9.361) 25 (kindly provided by Dr Ulrich Hammerling) at 4 uC for 30 min. After incubation the cells were washed twice and incubated for additional 30 min with streptavidin-conjugated APC on ice (BD Pharmingen). The splenic B cells were thereafter separated into FO B cells and MZ B cells as described above and further analyzed for their FccRIIb expression using FACS LSR SORP and the FACS Diva software 5.1 (BD Biosciences).
ELISpot
Ninety-six-well plates (MaxiSorp; NuncBrand Thermo Fischer Scientific) were coated over night at 4 uC with 50 ml of 0.2 mg/ml BCII or OVA, and bovine serum albumin (BSA) fraction V (Sigma) as an irrelevant control protein. The plates were washed with phosphate-buffered saline and 10 6 splenocytes, lymph nodes or bone marrow cells or 4310 5 -10310 5 sorted MZ or FO B cells diluted in 200 ml complete DMEM medium were added to each well. A minimum of eight wells per lymphoid tissue were analyzed, while MZ and FO B cells were analyzed in 1-5 wells, depending on the number of cells gained after cell sorting. The cells were cultured for 20-22 h at 37 uC in a 5% CO 2 atmosphere. After washing, alkaline phosphatase-conjugated sheep anti-mouse IgM or IgG (Sigma) was added to the plates and incubated for 2 h at room temperature or over night at 4 uC. After washing with 0.2 M Tris buffer at pH 9.1, 50 ml of BCIP/NBT liquid substrate system (Sigma) was added to each well. The development of AFCs seen as spots was monitored for up to 1 h and the reaction was stopped by washing the plates with distilled water. The spots were counted under an inverted microscope (Leitz Diavert, Wetzlar, Germany). A mean value of spots in the wells were calculated and adjusted when necessary to the number of spots per 10 7 cells. In addition, the spots of the sorted MZ and FO B cells were adjusted to the number of spots per spleen. The IgG subclass ELISpot was performed as described above except that biotinconjugated goat anti-mouse IgG1, IgG2a, IgG2b and IgG3 Abs (Southern Biotech) were added to the plates and incubated over night at 4 uC. The plates were washed and alkaline phosphatase-conjugated ExtrAvidin (Sigma) was added and incubated for 2 h at room temperature. Spots were developed with BCIP/NBT liquid substrate system as described above.
Immunofluorescence Spleens were removed from unimmunized DBA/1 mice and from CIIimmunized DBA/1 mice on days 7 and 28 after immunization. The spleens were snap-frozen in Killik cryostat embedding medium (BioOptica, Milan, Italy) and were kept at 270 uC until sectioned. Cryostat sections were cut at 8-10 mm, fixed in acetone and blocked with 1 : 20 diluted goat sera for 15 min prior to staining. After additional washes, the sections were incubated with MOMA-1 conjugated to FITC (anti-CD169) (AbD serotec, Düsseldorf, Germany), anti-CD3 conjugated to PE or anti-B220 conjugated to PE in combination with biotinylated anti-CD9 (BD Pharmingen) for 1 h. The sections were washed and either incubated with streptavidin-conjugated APC for 30 min or mounted in Fluoromount-G (Southern Biotech). APC-stained sections were further washed and mounted. In addition, consecutive sections were stained with isotype control Abs (BD Pharmingen). The sections were analyzed using a confocal microscope (LSM 510 Meta; Carl Zeiss, Jena, Germany).
Statistics
The Student's t-test was used for analyzing the sorted MZ and FO B cells, FccRIIb expression, the number of AFCs in different mouse strains and between CII-and OVA-immunized mice. P,0.05 was considered statistically significant.
RESULTS
The spleen is largely responsible for the initial B-cell response to CII DBA/1 mice immunized with CII in complete Freund's adjuvant were analyzed to explore the lymphoid sites where CII-reactive B cells are initiated in CIA. Thus, the CII-specific AFC was investigated by ELISpot in the spleen, lymph nodes and bone marrow at different time points after immunization.
Naive DBA/1 mice and DBA/1 mice immunized with OVA served as controls, as OVA represents a foreign Ag that does not mimic an autoAg nor induce arthritis. Interestingly, when analyzing unimmunized (week 0) DBA/1 mice, we found that naive splenic B cells responded to CII (Figure 1a and d) . The majority of the CII-reactive B cells produced IgM; however, IgG-positive cells could also be observed. Although the number of CII-specific AFCs in the naive spleen was low, it was significant, as no such reactivity was observed in the lymph nodes and bone marrow or towards OVA (CII versus OVA, P,0.001 for IgM AFCs and P,0.001-0.01 for IgG AFCs) (Figure 1a-f) . Neither could any AFC be observed in the naive spleen when BSA, representing another bovine Ag, was used as coating agent (data not shown).
After CII immunization, the number of IgM anti-CII AFCs in the spleen increased rapidly, peaked at 2 weeks and subsequently declined at 4 weeks after immunization (Figure 1a) . The AFC pattern in the lymph nodes was similar, but the number of IgM anti-CII AFCs was fewer (Figure 1b) . The bone marrow demonstrated in general very few IgM anti-CII AFCs (Figure 1c ). Interestingly and in contrast to the CII-immunized mice, OVA-immunized mice did not develop an early and strong IgM Ab response in the spleen (CII versus OVA, P,0.01, weeks 1 and 2) (Figure 1a) . Instead, these animals displayed a somewhat greater IgM anti-OVA response in the lymph nodes 1 week after immunization, which increased at 2 weeks and subsequently declined thereafter (Figure 1b) . Very few IgM anti-OVA AFCs were seen in the bone marrow of OVA-immunized mice (Figure 1c) .
The number of splenic IgG anti-CII AFCs in CII-immunized mice was fewer compared with that of the splenic IgM anti-CII AFCs (Figure 1a and d) . Nevertheless, an early production of IgG anti-CII was observed that remained relatively constant throughout the experiment (Figure 1d ). The IgG anti-CII response in the lymph nodes was somewhat delayed compared to the spleen; instead, a significant number of IgG anti-CII AFCs was demonstrated 4 weeks after CII (Figure 1e) , a time point when the mice start to develop CIA (Supplementary Figure 2) . Nine weeks after CII immunization, and at a more late stage of the disease (Supplementary Figure 2) , the number of IgG anti-CII AFCs in the lymph nodes declined, whereas the IgG anti-CII AFCs in the bone marrow increased substantially (Figure 1e and f) . In OVA-immunized mice, the IgG anti-OVA response in the spleen was most evident 4 weeks after immunization (Figure 1d) . A similar pattern was observed in the bone marrow, while the response in the lymph nodes peaked at 2 weeks after immunization (Figure 1e-f) . The number of OVA-specific IgG AFCs in the lymph nodes declined 9 weeks after immunization, and this was also observed in the bone marrow, which displayed less IgG AFCs than CII-immunized mice (CII versus OVA, P,0.01) (Figure 1d-f) . When compiling the ELISpot data from spleen and lymph nodes for the first 2 weeks after immunization, it was evident that the majority of the humoral response to CII principally started in the spleen (Figure 1g) . Even prior to CII immunization, noticeable IgM and IgG responses to CII were present in the spleen (week 0). In contrast, IgM and IgG responses to OVA started essentially in the lymph nodes rather than in the spleen of OVA-immunized mice (Figure 1h) . Additionally, the total number of IgM AFCs during the first 2 weeks after immunization appeared higher in CII-immunized animals, while the total IgG AFCs were comparable in CII-and OVA-immunized mice (Figure 1g and h) . This indicates that the autoimmune B-cell response in CIA is preceded by an early CII-reactive response in the spleen.
CII elicits steady IgM serum titres
We next set out to investigate the kinetics of Ag-specific IgM and IgG in the sera of the immunized mice. Thus, anti-CII or anti-OVA Abs were analyzed at different time points after immunization by ELISA (Figure 1i and j) . Optical densityvalues of IgM anti-CII could be detected at 1 week after CII immunization that increased steadily, peaked at 4 weeks and thereafter stayed relatively constant throughout the experiment (Figure 1i ). IgG anti-CII Abs were, on the other hand, not observed until 2 weeks after immunization, but instead increased progressively thereafter and peaked at 9 weeks (at termination of the experiment). The Ab kinetics in OVA-immunized mice was different from that in the CII-immunized animals. Thus, the concentration of IgM anti-OVA peaked at 1 week after immunization, dropped rapidly at 2 weeks and stayed low thereafter (Figure 1j ). The Ag-specific IgG levels were much higher in OVA-immunized animals than in CIIimmunized animals (sera had to be diluted 25 times more) and could be detected already 1 week after immunization, peaked at 4 weeks and stayed relatively constant throughout the experiment. These results indicate that the serum IgM response is stable in mice immunized with CII compared to OVA, possibly reflecting the initial and numerous IgM anti-CII AFCs in these mice. Further, the delayed and weaker Ag-specific IgG serum response in CII-immunized mice in contrast to OVA-immunized animals shows that an auto-Ag needs to break tolerance in order to induce a potent IgG response. In addition, it should also be taken into account that anti-CII Abs may disseminate out to joints, where they bind joint cartilage, rather than stay in the circulation.
Autoimmune prone mice display CII reactivity in the spleen
The demonstrated natural reactivity against CII in DBA/1 mice led us to investigate whether other mouse strains also display similar reactivities. Thus, splenic cell suspensions were prepared from naive DBA/ 1, NOD, Balb/c and C57BL/6 mice and the presence of anti-CII AFCs using ELISpot was investigated. Interestingly, all strains except C57BL/ 6 mice displayed notable IgM and IgG AFCs to CII (Table 1) , while AFCs to a control bovine protein, BSA, were absent (data not shown). DBA/1 mice had significantly more IgM anti-CII AFCs than C57BL/6 mice (Pf0.05). No serum IgM or IgG anti-CII Abs could be demonstrated in the different naive mouse strains (DBA/1, NOD, Balb/c and C57BL/6) (data not shown).
MZ B cells harbour natural CII reactivity and expand after immunization
Since AFCs to CII were first detected in the spleen, we were interested to see if the anti-CII response could be related to a certain splenic Bcell population. Thus, splenocytes from naive and CII-immunized DBA/1 mice were separated into FO and MZ B cells by MACS and FACS sorting using CD1d and CD23 markers (Figure 2a Figure 2a) .
Migration of MZ B cells to the follicle following CII immunization
The rapid expansion of CII-reactive MZ B cells after immunization led us to investigate whether this MZ B-cell activation was associated with migration of the MZ B cells into the follicles, as MZ B-cell shuttling to follicles is related to Ag transportation. 26, 27 Thus, we analyzed the localization of MZ B cells in the spleen of CII-immunized mice in MZ B cells are involved in the initiation of CIA C Carnrot et al 300 comparison with unimmunized mice (Figure 3) . Spleen sections were stained with MOMA Abs (green) to detect metallophilic macrophages, located on the border between the marginal and FO zone, 28 together with CD3 (yellow) for T-cell identification, or B220 (red) and CD9 (blue) for B-cell and MZ B-cell detection. When comparing sections from unimmunized mice with that of CII-immunized mice (day 28), it was revealed that the T-cell zone in the follicle was smaller in the immunized animals ( Figure 3 ; first row) and that the B cell area inside the follicle was larger (Figure 3; second row) . However, the number of B cells located outside the follicle in the MZ was reduced in the immunized animals. By triple staining of MOMA, B220 and CD9, we could localize and identify MZ B cells (appearance in violet red) (Figure 3 ; third row). The MZ B cells were mainly located in the MZ outside the metallophilic macrophages, where unimmunized mice displayed a dense area of MZ B cells, while the CII-immunized mice had a more dispersed MZ B-cell area. In addition, when using a greater magnification it was revealed that MZ B cells were also present inside the follicles, especially in the CII-immunized animals, where the MZ B cells had gathered closely together in the follicle (Figure 3, bottom row) . Spleen sections from 1 week after CII immunization also demonstrated migrating MZ B cells into the follicle, but less prominent as seen at day 28 after immunization (data not shown).
The IgG subclass profiles differ between spleen and lymph nodes in CII-immunized mice It is known that some IgG subclasses are more pathogenic than others and IgG2a anti-CII Abs in particular have been associated with CIA. [29] [30] [31] However, monoclonal IgG1 and IgG2b anti-CII Abs can also induce arthritis in naive mice. 2 Thus, we were interested to investigate which IgG subclasses were generated at different lymphoid sites of mice immunized with CII. The subclasses of CII-reactive AFCs were analyzed by ELISpot 1 week after immunization in the spleen and 2 weeks after immunization in the lymph nodes, as the total IgG anti-CII AFCs in the lymph nodes mainly were observed after 2 weeks. Interestingly, IgG2b anti-CII AFCs were the dominating AFCs in the spleen 1 week after immunization, while at 2 and 4 weeks both IgG2b and IgG2a AFCs were mostly produced. The lymph nodes showed comparable percentages of IgG1, IgG2a and IgG2b anti-CII AFCs at 2 weeks after immunization, and a slight increase in IgG1 and IgG2b AFCs and a decrease in IgG2a AFCs at 4 weeks (Figure 4a) .
The IgG subclass-specific response in sera of the CII-immunized mice was evaluated and demonstrated similar levels of IgG1, IgG2a and IgG2b anti-CII Abs at 2 weeks after immunization (Figure 4b ) that increased further at 4 weeks with IgG1 excelling. IgG3 anti-CII Abs were just about detectable in the mice.
DISCUSSION
CII has an evolutionary conserved structure and immune dominant sequences of bovine and murine CII differ only with one single amino acid residue. 32 Thus, immunization with bovine CII will result in an immune response that is crossreactive to murine CII, which in the CIA model will elicit arthritis. One of the first and most significant observations we made was that naive DBA/1 mice exhibit clones of B cells with reactivity to CII without any previous exposure to the Ag. One could argue that the response might be unspecific, but the anti-CII response was not seen in the lymph nodes and neither a different bovine protein (BSA) or OVA generated such a response in the naive mice. The CII-reactive B cells produced mainly IgM, but few B cells also showed IgG reactivity. Notably, this finding was not unique to the DBA/1 strain, as B cells from the spleens of naive NOD and Balb/c mice also displayed reactivity to CII, while C57BL/6 mice exhibited almost no CII-specific AFC. This indicates that genetic background influences the natural B-cell reactivity to CII. In agreement, natural Abs are independent of internal or external stimuli, whereas genetic differences seem to influence their titres. show for example spontaneous reactivity to double-stranded DNA, a self-Ag in murine lupus. 15, 36, 37 Indeed, when we separated the splenic B cells from naive DBA/1 mice into FO and MZ B cells, we found that the majority of IgG anti-CII AFCs belonged to the MZ B-cell population, and after CII immunization the MZ B cells were the first to significantly expand. The activation of MZ B cells is probably facilitated by the actual structure of CII, functioning as a thymusindependent type 2 Ag, due to highly repetitive epitopes that may induce maximal crosslinking of the BCR. 38 MZ B cells are known to have high basal expression of CD80 and CD86, 13 suggesting that these B cells have been previously Ag primed. The costimulatory molecules will keep the MZ B cells in a pre-activated state making them easy to trigger. Thus, upon Ag activation the MZ B cells will rapidly generate effector B cells that can either present Ag to T cells or differentiate into plasma cells for an early boost of IgM Ab production. 13 Indeed, a rapid expansion of IgM anti-CII MZ B cells was particularly observed 1 week after CII immunization. The MZ B cells exhibited also faster IgG kinetics, as the FO B cells represented the later phase of the anti-CII response. Altogether, these data point towards an initial role of MZ B cells in the immune response to CII.
In contrast to the spleen, the B-cell response in the lymph nodes following CII immunization was somewhat delayed. However, the lymph nodes demonstrated the highest number of IgG anti-CII AFCs and at a time point when mice begin to develop CIA (4 weeks after immunization). Similarly, the bone marrow exhibited mainly IgG anti-CII AFCs at late time points after CII immunization, possibly representing immigrating plasma cells.
The immune response to a foreign Ag differed substantially compared to an auto-Ag. Thus, while the CII immunization generated mainly an early B-cell response in the spleen rather than in the lymph nodes, the opposite was observed in OVA-immunized mice, although identical immunization protocols were used. OVA immunization generated generally also fewer Ag-specific B cells, and a faster IgM and a stronger IgG serum response. The discrepancies in the immune responses are likely due to that the CII is regarded as self-Ag, which require breakage of tolerance for a full blown immune response to occur. Although more AFCs were induced in CII-immunized mice (likely due to the expansion of the pre-existing CII-reactive MZ B cells in the spleen of naive mice), secretion of self-reactive Abs was highly controlled (as reflected by the lower serum IgG anti-CII levels compared to IgG anti-OVA levels). Thus, self-reactive B cells seem to be strongly regulated, as indicated by the almost 40% higher expression of the inhibitory FccRIIb on MZ B cells compared to FO B cells in naive and CII-exposed mice. The FccRIIb expression on the MZ B cells increased after CII immunization, but not on FO B cells, probably in an attempt to repress IgG auto-Ab production. In fact, overexpression of FccRIIb on B cells in mice profoundly decreases IgG responses. 39 CIA is regarded as an IgG-mediated disease, but previous studies have also shown that IgM play an important role. 40 Thus, mice deficient in IgM (lacking both membrane and secreted IgM) develop significantly reduced CIA and decreased IgG2a anti-CII Abs. This may suggest that the strong IgM response, as evident by the numerous AFCs and prolonged IgM serum levels in CII-immunized mice, affects the generation of pathogenic IgG Abs. The early IgM anti-CII response was predominantly represented by MZ B cells. These B cells are potent activators of naive T cells, which may help in the activation of anergic self-reactive FO B cells.
14 Thus, it has been shown that anergic B cells can be drawn into proliferation if T helper (Th)-related signals are present. 41, 42 It is therefore interesting to note that numerous MZ B cells (possibly some CII-specific) have left the MZ after CII immunization and migrated into the follicles forming clusters in the B-cell zone where germinal centres normally are located. The MZ B cells may shuttle the CII into the follicle where they deposit the Ag on FO dendritic cells 27, 43 and/or present CII to T cells. 13, 14 Ag-specific T cells activated by MZ B cells have been shown to produce Th1 cytokines generating high interferon-c levels.
14 Interferon-c stimulates class switch recombination to IgG2a and IgG2b, and indeed, IgG2b and IgG2a subclasses dominated the isotype profile of the CII-reactive AFCs in the spleen at 2 and 4 weeks after immunization. This isotype pattern differed from the CII-reactive AFCs in lymph nodes, showing a mix of Th1-/Th2-dependent isotypes at 2 weeks that shifted into a prominent Th2-influenced IgG1 response at 4 weeks. This corresponds well with an earlier report of Doncarli et al. 44 demonstrating Th2 responses appearing after CIA onset. Notably, the subclass-specific B-cell response in the lymph nodes of the CII-immunized mice correlated with the subclass pattern in the sera. Thus, similar IgG1, IgG2a and IgG2b anti-CII responses were observed in lymph nodes and in sera of CII-immunized mice, with IgG1 peaking at 4 weeks. IgG1 Abs are indeed pathogenic, shown by the induction of arthritis in naive mice upon transfer of IgG1 anti-CII Abs and the dominance of IgG1 arthritis-inducing Abs in the K/BxN arthritis model. 2, 45 These data suggest that the IgG anti-CII response in the lymph nodes, probably influenced by the early anti-CII events in the spleen, is contributing to the circulating and pathogenic anti-CII Abs in CIA.
Our results of spontaneous CII-reactive MZ B cells and later activated FO B cells in CIA are in accordance with findings in a low affinity Ig BCR transgene, specific for the glucose-6-phosphate isomerase (GPI) auto-Ag associated with the K/BxN arthritis model. 46 Two functionally distinct populations of GPI-binding B cells were identified, one enriched in the splenic MZ that were competent to spontaneously proliferate and secrete Ig, and the other in the recirculating FO pool that were ignorant to self-Ag. However, the FO anti-GPI B cells could be activated to secrete auto-Abs when given GPI-specific T-cell help. Thus, these and our data indicate that self-reactive B cells can participate in auto-Ab responses in both T cell-dependent and -independent mechanisms.
In conclusion, we have demonstrated that naive mice display CIIreactive MZ B cells that upon CII immunization expand rapidly. Subsequently, numerous CII-reactive FO B cells are generated in the spleen and lymph nodes. These data suggest that MZ and FO B cells act at different stages to initiate the autoimmune response, where the MZ B cells may be the catalyst for driving the FO B cell responses to CII. Further studies are though needed to determine the exact mechanisms of MZ B cells in CIA.
Note: Supplementary information is available on the Cellular & Molecular Immunology website (http://www.nature.com/cmi/).
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